|
Market Closed –
|
|
|||
|
807.19 USD |
+4.33% |
803.85 |
-0.41% | |
Published on 06/11/2025 at 07:01
This article is reserved for members Unlock the article: REGISTER NOW!
© Reuters – 2025
|
Health Rounds: Patients drop fewer pounds with weight-loss drugs in real world than in trials |
07:01am |
RE |
|
Health Care Up on Sales Optimism — Health Care Roundup |
Jun. 10 |
DJ |
|
Drug pricing reform talks with US government lack clarity, industry executives say |
Jun. 10 |
RE |
|
Drug pricing reform talks with US government lack clarity, industry executives say |
Jun. 10 |
RE |
|
Sector Update: Health Care Stocks Rise Late Afternoon |
Jun. 10 |
MT |
|
Lilly to Only Work With Telehealth Companies That Don’t Sell Copycat Zepbound |
Jun. 10 |
MT |
|
Sector Update: Health Care Stocks Higher Tuesday Afternoon |
Jun. 10 |
MT |
|
Metsera rises as experimental weight-loss drug shows promise in small early-stage trial |
Jun. 10 |
RE |
|
Lilly to Only Work With Telehealth Companies That Don’t Sell Copycat Zepbound |
Jun. 10 |
MT |
|
Lilly to Only Work With Telehealth Companies That Don’t Sell Copycat Zepbound, Bloomberg Reports |
Jun. 10 |
MT |
|
Novo Nordisk starts new CagriSema weightloss drug trial |
Jun. 10 |
RE |
|
Eli Lilly and Company Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-10-2025 08:00 AM |
Jun. 10 |
|
|
The Parvus fund enters Novo Nordisk’s capital |
Jun. 10 |
 |
|
Activist fund reported to be building position in Novo Nordisk – FT |
Jun. 10 |
FW |
|
Activist hedge fund Parvus builds stake in Novo Nordisk, FT reports |
Jun. 09 |
RE |
|
Novo Nordisk Faces Pressure From Parvus Over CEO Search |
Jun. 09 |
MT |
|
Eli Lilly Weight-Loss Drug India Sales Jump 60% in May From April |
Jun. 09 |
MT |
|
Health Care Climbs as Omada Surges on Debut – Health Care Roundup |
Jun. 06 |
DJ |
|
Novo’s Ozempic linked to rare cases of serious eye disorder, EU regulator says |
Jun. 06 |
RE |
|
TD Cowen Adjusts Price Target on Eli Lilly and Company to $960 From $1,050, Maintains Buy Rating |
Jun. 05 |
MT |
|
Signify Bio announced that it has received $15 million in funding from Eli Lilly and Company, Actium Group LLC, BrightEdge LLC, Bill & Melinda Gates Foundation, Endowment arm, Danaher Ventures LLC |
Jun. 04 |
CI |
|
Welldoc Says Working With Lilly To Launch Personalized Health & Medicine Platform |
Jun. 04 |
RE |
|
Wegovy on the rise amongst American teens; between effectiveness and reluctance |
Jun. 04 |
|
|
Eli Lilly Licenses Camurus’ FluidCrystal Tech for Cardiometabolic Drugs |
Jun. 04 |
MT |
|
Camurus enters into collaboration with Eli Lilly – could generate billions |
Jun. 04 |
FW |
LLY: Dynamic Chart
Eli Lilly and Company is one of the world’s leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
– endocrinology (65.5%): products for treating osteoporosis, diabetes, and growth problems;
– oncology (19.4%);
– immunology diseases (9.8%);
– neurology (3.3%): primarily drugs used in treating depression and schizophrenia;
– other (2%).
Net sales are distributed geographically as follows: the United States (67.4%), Europe (15.4%), Japan (4%), China (3.7%) and other (9.5%).
More about the company
Buy
Last Close Price
807.19USD
Average target price
951.98USD
Spread / Average Target
+17.94%
Consensus
Quarterly revenue – Rate of surprise
Select your edition
All financial news and data tailored to specific country editions
